Azitra, INC 8-K filings

Azitra, Inc. issues warrants to purchase common stock and grants participation rights in future financings to investors in connection with a previously disclosed common stock offering.

Azitra, Inc. has entered into a securities purchase agreement for a registered direct offering of common stock, expected to generate approximately $930,000 in gross proceeds.

Azitra, Inc. has successfully priced a public offering of common stock, raising approximately $1.5 million to support its clinical-stage biopharmaceutical programs.

Azitra Inc. held its 2024 Annual Meeting of Stockholders, electing four directors, approving amendments to its stock incentive plan, and ratifying its accounting firm.

Azitra Inc. announced its Q3 2024 financial results, highlighted by a $10 million follow-on offering and progress in clinical trials for its dermatology therapies.

Azitra, Inc., a clinical-stage biopharmaceutical company, announced its Q2 2024 financial results, highlighted by a $10 million follow-on offering and progress in its clinical programs.

Azitra, Inc., a clinical-stage biopharmaceutical company, has successfully closed a $10 million public offering of common stock and warrants.

Azitra Inc. has implemented a 1-for-30 reverse stock split after receiving shareholder approval at a special meeting on June 27, 2024.

Azitra, Inc., a clinical-stage biopharmaceutical company, announced its Q1 2024 financial results and provided updates on its clinical programs, including progress on ATR-12 and ATR-04.

Azitra, Inc., a clinical-stage biopharmaceutical company, announced its full year 2023 financial results and provided a business update, highlighting progress in its clinical programs and financial activities.

Azitra, Inc., a clinical-stage biopharmaceutical company, has announced the pricing of a $5 million public offering of 16,667,000 shares of common stock at $0.30 per share.